Neil - your 'scenario' has absolutely nothing to do with my post relating to figures of revenue, cash and basic income performance since 1st July 2020 !
I spent time on it with a little personal commentary to outline for everyone the overall picture since then whereas you're jumping in with a 1-week scenario possibility on s/p & m/c ...?? Really ??
I've left Sholom's excuses/comments (related here on HC by your good self) out of it, where he attempts to blame shareholders for holding up and/or losing first-mover impetus - that relates back to 2018/2019 and 2019/2020 - no need for it because the company has clearly displayed financial dilapidation and management ineptitude all by their own doing since that accusation up to the present day.
They created the downward spiral - not shareholders.
Look, I haven't even included the couple hundred grand interest from the past coupla years.
Your scenario can possibly have a shorterm effect of course but again, it's got nothing to do with the actual running of the company over the longer term as we have painfully continued to witness.
In fact - quickly back to the many relisting prospectus' - don't you think the company tried their own first-mover attempt on shareholders which failed ??
Remember they tried to do a further cap raise which had to be pulled ?
Yup, that was the one at 8c which in today's figures at post consolidation is TWO DOLLARS !
Talk about trying to take a first-mover advantage when the current post-consolidation s/p is TWO-POINT-ONE-CENTS !
Btw, you wrote above in your scenario '0.08 cents' - but I know you meant 8 cents
- Forums
- ASX - By Stock
- CGB
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-84
-
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online